<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36252589</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1678-4227</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Arquivos de neuro-psiquiatria</Title><ISOAbbreviation>Arq Neuropsiquiatr</ISOAbbreviation></Journal><ArticleTitle>Characterization of the nigroestriatal system in a sample of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>806</StartPage><EndPage>811</EndPage><MedlinePgn>806-811</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0042-1755282</ELocationID><Abstract><AbstractText Label="BACKGROUND">The coexistence of amyotrophic lateral sclerosis (ALS) with clinical forms of Parkinson disease (PD), although uncommon, is found to a greater degree than one would expect by chance. The pathological mechanisms of ALS and PD are still not fully understood, and the coexistence of these two diseases suggests that they could share mechanisms in common.</AbstractText><AbstractText Label="OBJECTIVE">Here we present a sample of patients with clinically definitive or probable ALS who were evaluated with single-photon emission computed tomography SPECT/TRODAT and compared with non-ALS controls.</AbstractText><AbstractText Label="METHODS">Patients with clinically definite or probable ALS were assessed with the amyotrophic lateral sclerosis functional rating scale (ALSFRS) to define severity and had their demographic data collected. The TRODAT results of patients with ALS were compared with those of patients with a diagnosis of PD with less than 10 years of duration, and with patients with a diagnosis of others movement disorders not associated with neurodegenerative diseases.</AbstractText><AbstractText Label="RESULTS">A total of 75% of patients with ALS had TRODAT results below the levels considered normal; that was also true for 25% of the patients in the control group without neurodegenerative disease, and for 100% of the patients in the PD group. A statistically significant difference was found between patients with ALS and the control group without neurodegenerative disease in the TRODAT values&#x2009;&lt;&#x2009;0.05.</AbstractText><AbstractText Label="CONCLUSIONS">Our study fits with the neuropathological and functional evidence that demonstrates the existence of nigrostriatal dysfunction in patients with ALS. Further research to better understand the role of these changes in the pathophysiological process of ALS needs to be performed.</AbstractText><CopyrightInformation>Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monsalve</LastName><ForeName>Claudio Alejandro Jimenez</ForeName><Initials>CAJ</Initials><Identifier Source="ORCID">0000-0002-1652-5165</Identifier><AffiliationInfo><Affiliation>Hospital Simon Bol&#xed;var, Departamento de Neurologia, Bogot&#xe1;, Col&#xf4;mbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornari</LastName><ForeName>Luis Henrique Tieppo</ForeName><Initials>LHT</Initials><Identifier Source="ORCID">0000-0001-5244-9393</Identifier><AffiliationInfo><Affiliation>Irmandade Santa Casa de Miseric&#xf3;rdia de Porto Alegre, Departamento de Neurologia, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xfa;nior</LastName><ForeName>Neivo da Silva</ForeName><Initials>NDS</Initials><Identifier Source="ORCID">0000-0002-1663-5305</Identifier><AffiliationInfo><Affiliation>Irmandade Santa Casa de Miseric&#xf3;rdia de Porto Alegre, Departamento de Medicina Nuclear, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakata</LastName><ForeName>Douglas Tomio</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0001-9295-0254</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre, Faculdade de Medicina, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neto</LastName><ForeName>Eur&#xed;pedes Gomes de Carvalho</ForeName><Initials>EGC</Initials><Identifier Source="ORCID">0000-0002-5124-7877</Identifier><AffiliationInfo><Affiliation>Irmandade Santa Casa de Miseric&#xf3;rdia de Porto Alegre, Departamento de Neurologia, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotta</LastName><ForeName>Francisco Tellechea</ForeName><Initials>FT</Initials><Identifier Source="ORCID">0000-0002-9954-191X</Identifier><AffiliationInfo><Affiliation>Neurologista e Cl&#xed;nica Neurofisiologista, Intercoastal Medical Group, Sarasota, Fl&#xf3;rida, Estados Unidos.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieder</LastName><ForeName>Carlos Roberto de Mello</ForeName><Initials>CRM</Initials><Identifier Source="ORCID">0000-0003-2950-7211</Identifier><AffiliationInfo><Affiliation>Irmandade Santa Casa de Miseric&#xf3;rdia de Porto Alegre, Departamento de Neurologia, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Federal de Ci&#xea;ncias da Sa&#xfa;de de Porto Alegre, Faculdade de Medicina, Porto Alegre, RS, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Caracteriza&#xe7;&#xe3;o do sistema nigroestriatal em uma amostra de pacientes com esclerose lateral amiotr&#xf3;fica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arq Neuropsiquiatr</MedlineTA><NlmUniqueID>0125444</NlmUniqueID><ISSNLinking>0004-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">&#x2003;A coexist&#xea;ncia da esclerose lateral amiotr&#xf3;fica (ELA) com formas cl&#xed;nicas da doen&#xe7;a de Parkinson (DP), embora incomum, &#xe9; encontrada em um grau maior do que seria esperado ao acaso. Os mecanismos patol&#xf3;gicos da ELA e da DP ainda n&#xe3;o s&#xe3;o totalmente compreendidos e a coexist&#xea;ncia dessas duas doen&#xe7;as sugere que elas podem compartilhar mecanismos em comum.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">&#x2003;Apresentamos uma amostra de pacientes com ELA clinicamente definida ou prov&#xe1;vel que foram avaliados com tomografia computadorizada por emiss&#xe3;o de f&#xf3;ton &#xfa;nico (SPECT)/TRODAT e comparados com controles sem ELA. M&#xe9;TODOS: &#x2003;Pacientes com ELA clinicamente definida ou prov&#xe1;vel foram avaliados com a escala funcional de esclerose lateral amiotr&#xf3;fica (ALSFRS) para definir a gravidade e foram coletados os seus dados demogr&#xe1;ficos. Os resultados do TRODAT de pacientes com ELA foram comparados com aqueles de pacientes com diagn&#xf3;stico de DP com menos de 10 anos de dura&#xe7;&#xe3;o e com pacientes com diagn&#xf3;stico de outros dist&#xfa;rbios do movimento n&#xe3;o associados a doen&#xe7;as neurodegenerativas.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">&#x2003;Um total de 75% dos pacientes com ELA apresentou resultados de TRODAT abaixo dos n&#xed;veis considerados normais; 25% no grupo controle sem doen&#xe7;a neurodegenerativa e 100% no grupo DP. Uma diferen&#xe7;a estatisticamente significativa foi encontrada entre os pacientes com ELA e o grupo controle sem doen&#xe7;a neurodegenerativa nos valores de TRODAT <i>p</i>&#x2009;&lt;&#x2009;0,05. CONCLUS&#xf5;ES: &#x2003;Nosso estudo est&#xe1; de acordo com as evid&#xea;ncias neuropatol&#xf3;gicas e funcionais que demonstram a exist&#xea;ncia de disfun&#xe7;&#xe3;o nigroestriatal em pacientes com ELA. Mais pesquisas para entender melhor o papel dessas mudan&#xe7;as no processo fisiopatol&#xf3;gico da ELA precisam ser realizadas.</AbstractText><CopyrightInformation>Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).</CopyrightInformation></OtherAbstract><CoiStatement>The authors have no conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>17</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36252589</ArticleId><ArticleId IdType="pmc">PMC9703885</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1755282</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boill&#xe9;e S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52(01):39&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ. 2008;336(7645):658&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270983</ArticleId><ArticleId IdType="pubmed">18356234</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiryaki E, Horak HA. ALS and Other Motor Neuron Diseases. Continuum. 2014;20(05):1185&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25299277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zo&#x11f;uz A, Uyan &#xd6;, Birdal G, et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiol Aging. 2015;36(04):1764.e9&#x2013;1764.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591733</ArticleId><ArticleId IdType="pubmed">25681989</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33(04):807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, Oda M, Tanabe H. Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1993;19(04):300&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">7901781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert RMW, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord. 2010;25(12):1868&#x2013;1875. doi: 10.1002/mds.23200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23200</ArticleId><ArticleId IdType="pubmed">20669307</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015;33(04):855&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HK, Lim YM, Kim JS, et al. Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. J Neurol Sci. 2011;301(1-2):12&#x2013;13. doi: 10.1016/j.jns.2010.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.11.017</ArticleId><ArticleId IdType="pubmed">21167502</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogels OJM, Veltman J, Oyen WJ, Horstink MW. Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor downregulation versus striatal cell degeneration. J Neurol Sci. 2000;180(1-2):62&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma KR, Sheriff S, Maudsley A, Govind V. Diffusion tensor imaging of basal ganglia and thalamus in amyotrophic lateral sclerosis. J Neuroimaging. 2013;23(03):368&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896398</ArticleId><ArticleId IdType="pubmed">22273090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Momose T, Shimizu J, Tsuji S, Kwak S. A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis. Arch Neurol. 2006;63(12):1719&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, Linke R, Schwarz J, et al. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry. 1998;65(02):263&#x2013;265. doi: 10.1136/jnnp.65.2.263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.65.2.263</ArticleId><ArticleId IdType="pmc">PMC2170216</ArticleId><ArticleId IdType="pubmed">9703186</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Snow BJ, Bhatt MH, Peppard R, Eisen A, Calne DB. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet. 1993;342(8878):1016&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105264</ArticleId></ArticleIdList></Reference><Reference><Citation>Deriu M, Murgia D, Paribello A, Marcia E, Melis M, Cossu G. Pisa syndrome as presenting symptom of amyotrophic lateral sclerosis. J Neurol. 2011;258(11):2087&#x2013;2089. doi: 10.1007/s00415-011-6057-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6057-2</ArticleId><ArticleId IdType="pubmed">21516360</ArticleId></ArticleIdList></Reference><Reference><Citation>Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson&#x2019;s disease. Mol Psychiatry. 2014;19(03):358&#x2013;367. doi: 10.1038/mp.2013.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.3</ArticleId><ArticleId IdType="pmc">PMC5116056</ArticleId><ArticleId IdType="pubmed">23399912</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>